Loading...
Market
What will public perception be on Ozempic's use beyond diabetes by end of 2024?
2
Resolution / Starting Odds
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Public opinion polls and surveys
Story
Study Finds Ozempic Cuts Alzheimer's Risk by 70% in Type 2 Diabetes
Oct 24, 2024, 11:11 AM
An observational study analyzing medical records has found that semaglutide, the active ingredient in diabetes medications like Ozempic and Wegovy developed by Novo Nordisk, may significantly reduce the risk of Alzheimer's disease in people with type 2 diabetes. The study, published Thursday, showed that patients taking Ozempic had a 70% lower risk of being diagnosed with Alzheimer's compared to those taking other diabetes drugs. This finding suggests potential benefits of semaglutide in neurodegenerative diseases beyond its established use in managing diabetes and aiding weight loss.
View original story
Similar markets
Increased Coverage • 25%
Decreased Coverage • 25%
No Change • 25%
Other Health Risks Highlighted • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
By Novo Nordisk • 25%
By health organizations • 25%
By both • 25%
No campaigns • 25%
Yes • 50%
No • 50%
Ban the drugs • 25%
Issue safety warnings • 25%
No action taken • 25%
Other actions • 25%
Significant improvement in affordability perception • 25%
Slight improvement in affordability perception • 25%
No change in affordability perception • 25%
Worsening perception of affordability • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
No new data released • 25%
Reduction below 20% • 25%
Reduction between 20% and 30% • 25%
Reduction above 30% • 25%